Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK-1167-011 | Other Identifier | MSD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine.
The goals of the trial are to learn:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1: MK-1167 Form 2 | Experimental | Participants receive MK-1167 Form 2 orally. |
|
| Arm 2: MK-1167 Form 1 | Experimental | Participants receive MK-1167 Form 1 orally. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK-1167 | Drug | Oral administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Curve from Time 0 to Infinity (AUC0-inf) of MK-1167 | Blood samples will be collected to determine the AUC0-inf of MK-1167. | At designated time points (up to approximately 21 days) |
| Maximum Plasma Concentration (Cmax) of MK-1167 | Blood samples will be collected to determine the Cmax of MK-1167. | At designated time points (up to approximately 21 days) |
| Area Under the Curve from Time 0 to Last Measurable Concentration (AUC0-last) of MK-1167 | Blood samples will be collected to determine the AUC0-last of MK-1167. | At designated time points (up to approximately 21 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Curve from Time 0 to 24 hours (AUC0-24) of MK-1167 | Blood samples will be collected to determine the AUC0-24 of MK-1167. | At designated time points (up to approximately 24 hours) |
| Concentration at 24 hours (C24) of MK-1167 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| QPS-MRA, LLC ( Site 0001) | South Miami | Florida | 33143 | United States |
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples will be collected to determine the C24 of MK-1167.
| At designated time points (up to approximately 24 hours) |
| Time to Maximum Serum Concentration (Tmax) of MK-1167 | Blood samples will be collected to determine the Tmax of MK-1167. | At designated time points (up to approximately 21 days) |
| Apparent Terminal Half-life (t1/2) of MK-1167 | Blood samples will be collected to determine the t1/2 of MK-1167. | At designated time points (up to approximately 21 days) |
| Apparent Clearance after Nonintravenous Administration (CL/F) of MK-1167 | Blood samples will be collected to determine the CL/F of MK-1167. | At designated time points (up to approximately 21 days) |
| Apparent Volume of Distribution during Terminal Phase (Vz/F) of MK-1167 | Blood samples will be collected to determine the Vz/F of MK-1167. | At designated time points (up to approximately 21 days) |
| Number of Participants Who Experience One or More Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported. | Up to approximately 78 days |
| Number of Participants Who Discontinue Study Intervention Due to an AE | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported. | Up to approximately 36 days |